Current Breast Cancer Reports

, Volume 1, Issue 1, pp 12–20 | Cite as

How do we evaluate sentinel nodes and interpret the findings?



Sentinel lymph node (SLN) biopsy has become standard care for axillary lymph node staging, allowing routine, pathologic SLN examination by serial sections (SS) and/or immunohistochemical (IHC) stains. Although these methods increase the accuracy of staging, the prognostic significance of SLN micrometastases (pN0i+ [< 0.2 mm] and pN1mi [0.2–2 mm]), and especially of those detected only by IHC, is controversial. Retrospective studies have addressed this issue by relating survival to size of nodal metastasis, or by using SS and/or IHC to reassess nodes initially staged as negative, and suggest but do not conclusively prove that SLN micrometastases are associated with a modest decrement in overall and/or disease-free survival. Because there is no current standardized protocol for the pathologic assessment of SLN, prospective trials in progress will establish whether SS and/or IHC are worthwhile.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Kim T, Giuliano AE, Lyman GH: Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma. Cancer 2006, 106:4–16.PubMedCrossRefGoogle Scholar
  2. 2.
    Veronesi U, Paganelli G, Viale G, et al.: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003, 349:546–553.PubMedCrossRefGoogle Scholar
  3. 3.
    Purushotham AD, Upponi S, Klevesath MB, et al.: Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005, 23:4312–4321.PubMedCrossRefGoogle Scholar
  4. 4.
    Mansel RE, Fallowfield L, Kissin M, et al.: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006, 98:599–609.PubMedGoogle Scholar
  5. 5.
    Krag DN, Anderson SJ, Julian TB, et al.: Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007, 8:881–888.PubMedCrossRefGoogle Scholar
  6. 6.
    Turner RR, Ollila DW, Krasne DL, et al.: Histologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg 1997, 226:271–278.PubMedCrossRefGoogle Scholar
  7. 7.
    Weaver DL, Krag DN, Ashikaga T, et al.: Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer 2000, 88:1099–1107.PubMedCrossRefGoogle Scholar
  8. 8.
    Giuliano AE, Dale PS, Turner RR, et al.: Improved staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995, 3:394–401.Google Scholar
  9. 9.
    Liberman L: Pathologic analysis of sentinel lymph nodes in breast carcinoma. Cancer 2000, 88:971–977.PubMedCrossRefGoogle Scholar
  10. 10.
    Van Zee KJ, Manasseh DM, Bevilacqua JL, et al.: A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003, 10:1140–1151.PubMedCrossRefGoogle Scholar
  11. 11.
    Huvos AG, Hutter RV, Berg JW: Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 1971, 173:44–46.PubMedCrossRefGoogle Scholar
  12. 12.
    Breast. In AJCC Cancer Staging Manual. Edited by Fleming ID, Cooper JS, Henson DE, et al. Philadelphia: Lippincott-Raven; 1997:171–178.Google Scholar
  13. 13.
    Greene FL, Page DL, Fleming ID, et al.: Breast. In AJCC Cancer Staging Manual. Edited by Greene FL, Page DL, Fleming ID, et al. New York: Springer; 2002:221–240.CrossRefGoogle Scholar
  14. 14.
    Attiyeh FF, Jensen M, Huvos AG, et al.: Axillary micrometastasis and macrometastasis in carcinoma of the breast. Surg Gynecol Obstet 1977, 144:839–842.PubMedGoogle Scholar
  15. 15.
    Rosen PP, Saigo PE, Bruan DW: Axillary micro and macrometastases in breast cancer. Prognostic significance of tumor size. Ann Surg 1981, 194:585–591.PubMedCrossRefGoogle Scholar
  16. 16.
    Fisher ER, Palekar A, Rockette H, et al.: Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4). V. Significance of axillary nodal micro- and macrometastases. Cancer 1978, 42:2032–2038.PubMedCrossRefGoogle Scholar
  17. 17.
    Colleoni M, Rotmensz N, Peruzzotti G, et al.: Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J Clin Oncol 2005, 23:1379–1389.PubMedCrossRefGoogle Scholar
  18. 18.
    Cox CE, Kiluk JV, Riker AI, et al.: Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg 2008, 206:261–268.PubMedCrossRefGoogle Scholar
  19. 19.
    Chen SL, Hoehne FM, Giuliano AE: The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann Surg Oncol 2007, 14:3378–3384.PubMedCrossRefGoogle Scholar
  20. 20.
    Saphir O, Amromin GD: Obscure axillary lymph-node metastasis in carcinoma of the breast. Cancer 1948, 1:238–241.PubMedCrossRefGoogle Scholar
  21. 21.
    Dowlatshahi K, Fan M, Snider HC, et al.: Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997, 80:1188–1197.PubMedCrossRefGoogle Scholar
  22. 22.
    Cote RJ, Peterson HF, Chaiwun B, et al.: Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group [see comments]. Lancet 1999, 354:896–900.PubMedCrossRefGoogle Scholar
  23. 23.
    Umekita Y, Ohi Y, Sagara Y, et al.: Clinical significance of occult micrometastases in axillary lymph nodes in “nodenegative” breast cancer patients. Jpn J Cancer Res 2002, 93:695–698.PubMedGoogle Scholar
  24. 24.
    Reed W, Bohler PJ, Sandstad B, et al.: Occult metastases in axillary lymph nodes as a predictor of survival in node-negative breast carcinoma with long-term follow-up. Breast J 2004, 10:174–180.PubMedCrossRefGoogle Scholar
  25. 25.
    Millis RR, Springall R, Lee AH, et al.: Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer 2002, 86:396–401.PubMedCrossRefGoogle Scholar
  26. 26.
    Cummings MC, Walsh MD, Hohn BG, et al.: Occult axillary lymph node metastases in breast cancer do matter: results of 10-year survival analysis. Am J Surg Pathol 2002, 26:1286–1295.PubMedCrossRefGoogle Scholar
  27. 27.
    Kahn HJ, Hanna WM, Chapman JA, et al.: Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system. Breast J 2006, 12:294–301.PubMedCrossRefGoogle Scholar
  28. 28.
    Tan LK, Giri D, Hummer AJ, et al.: Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol 2008, 26:1803–1809.PubMedCrossRefGoogle Scholar
  29. 29.
    Colpaert C, Vermeulen P, Jeuris W, et al.: Early distant relapse in “node-negative” breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour. J Pathol 2001, 193:442–449.PubMedCrossRefGoogle Scholar
  30. 30.
    Susnik B, Frkovic-Grazio S, Bracko M: Occult micrometastases in axillary lymph nodes predict subsequent distant metastases in stage I breast cancer: a case-control study with 15-year follow-up. Ann Surg Oncol 2004, 11:568–572.PubMedCrossRefGoogle Scholar
  31. 31.
    Braun S, Vogl FD, Naume B, et al.: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005, 353:793–802.PubMedCrossRefGoogle Scholar
  32. 32.
    International (Ludwig) Breast Cancer Study Group: Prognostic importance of occult axillary lymph node micrometastases from breast cancers. Lancet 1990, 335:1565–1568.Google Scholar
  33. 33.
    Wilkinson EJ, Hause LL, Hoffman RG, et al.: Occult axillary lymph node metastases in invasive breast carcinoma: characteristics of the primary tumor and significance of the metastases. Pathol Annu 1982, 17:67–91.PubMedGoogle Scholar
  34. 34.
    Morton DL, Wen DR, Wong JH, et al.: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127:392–399.PubMedGoogle Scholar
  35. 35.
    Alex JC, Krag DN: Gamma-probe guided localization of lymph nodes. Surg Oncol 1993, 2:137–143.PubMedCrossRefGoogle Scholar
  36. 36.
    Giuliano AE, Kirgan DM, Guenther JM, et al.: Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994, 220:391–401.PubMedCrossRefGoogle Scholar
  37. 37.
    Cserni G, Gregori D, Merletti F, et al.: Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg 2004, 91:1245–1252.PubMedCrossRefGoogle Scholar
  38. 38.
    Park J, Fey JV, Naik AM, et al.: A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg 2007, 245:462–468.PubMedCrossRefGoogle Scholar
  39. 39.
    Brogi E, Torres-Matundan E, Tan LK, et al.: The results of frozen section, touch preparation, and cytological smear are comparable for intraoperative examination of sentinel lymph nodes: a study in 133 breast cancer patients. Ann Surg Oncol 2005, 12:173–180.PubMedCrossRefGoogle Scholar
  40. 40.
    Wilke LG, McCall LM, Posther KE, et al.: Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006, 13:491–500.PubMedCrossRefGoogle Scholar
  41. 41.
    Cserni G, Amendoeira I, Apostolikas N, et al.: Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol 2004, 57:695–701.PubMedCrossRefGoogle Scholar
  42. 42.
    Cserni G, Bianchi S, Boecker W, et al.: Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. Cancer 2005, 103:358–367.PubMedCrossRefGoogle Scholar
  43. 43.
    Bleiweiss IJ, Nagi CS, Jaffer S: Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol 2006, 24:2013–2018.PubMedCrossRefGoogle Scholar
  44. 44.
    Carter BA, Jensen RA, Simpson JF, et al.: Benign transport of breast epithelium into axillary lymph nodes after biopsy. Am J Clin Pathol 2000, 113:259–265.PubMedCrossRefGoogle Scholar
  45. 45.
    Moore KH, Thaler HT, Tan LK, et al.: Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma: biologic metastasis or procedural artifact? Cancer 2004, 100:929–934.PubMedCrossRefGoogle Scholar
  46. 46.
    Wilke LG, Giuliano A: Sentinel lymph node biopsy in patients with early-stage breast cancer: status of the National Clinical Trials. Surg Clin North Am 2003, 83:901–910.PubMedCrossRefGoogle Scholar
  47. 47.
    Rutgers EJ, Meijnen P, Bonnefoi H: Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res 2004; 6:165–169.PubMedCrossRefGoogle Scholar
  48. 48.
    Rutgers EJT: Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases. J Clin Oncol 2008, 26:698–702.PubMedCrossRefGoogle Scholar
  49. 49.
    Neville AM: Breast cancer micrometastases in lymph nodes and bone marrow are prognostically important. Ann Oncol 1991, 2:13–14.PubMedGoogle Scholar
  50. 50.
    Trojani M, de Mascarel I, Coindre JM, Bonichon F: Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987, 55:303–306.PubMedGoogle Scholar
  51. 51.
    De Mascarel I, Bonichon F, Coindre JM, et al.: Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up. Br J Cancer 1992, 66:523–527.PubMedGoogle Scholar
  52. 52.
    Hainsworth PJ, Tjandra JJ, Stillwell RG, et al.: Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993, 80:459–463.PubMedCrossRefGoogle Scholar
  53. 53.
    McGuckin MA, Cummings MC, Walsh MD, et al.: Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer 1996, 73:88–95.PubMedGoogle Scholar
  54. 54.
    Nasser IA, Lee AK, Bosari S, et al.: Occult axillary lymph node metastases in “node-negative” breast carcinoma. Hum Pathol 1993, 24:950–957.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Department of Surgery, Breast ServiceMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations